MY160665A - Spiropiperidine compounds as orl-1 receptor antagonists - Google Patents

Spiropiperidine compounds as orl-1 receptor antagonists

Info

Publication number
MY160665A
MY160665A MYPI2012002117A MYPI2012002117A MY160665A MY 160665 A MY160665 A MY 160665A MY PI2012002117 A MYPI2012002117 A MY PI2012002117A MY PI2012002117 A MYPI2012002117 A MY PI2012002117A MY 160665 A MY160665 A MY 160665A
Authority
MY
Malaysia
Prior art keywords
orl
receptor antagonists
spiropiperidine compounds
spiropiperidine
compounds
Prior art date
Application number
MYPI2012002117A
Other languages
English (en)
Inventor
Belen Benito Collado Ana
Diaz Buezo Nuria
Maria Jimenez-Aguado Alma
Lafuente Blanco Celia
Angeles Martinez-Grau Maria
Pedregal-Tercero Concepcion
Angel Toledo Escribano Miguel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY160665A publication Critical patent/MY160665A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2012002117A 2009-11-16 2010-11-10 Spiropiperidine compounds as orl-1 receptor antagonists MY160665A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
MY160665A true MY160665A (en) 2017-03-15

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012002117A MY160665A (en) 2009-11-16 2010-11-10 Spiropiperidine compounds as orl-1 receptor antagonists

Country Status (34)

Country Link
US (1) US8232289B2 (enExample)
EP (1) EP2501703B1 (enExample)
JP (1) JP5680101B2 (enExample)
KR (1) KR101363830B1 (enExample)
CN (1) CN102612520B (enExample)
AR (1) AR078863A1 (enExample)
AU (1) AU2010319581C1 (enExample)
CA (1) CA2796161C (enExample)
CO (1) CO6541545A2 (enExample)
CR (1) CR20130087A (enExample)
DK (1) DK2501703T3 (enExample)
DO (1) DOP2012000135A (enExample)
EA (1) EA020848B1 (enExample)
EC (1) ECSP12011902A (enExample)
ES (1) ES2435814T3 (enExample)
HN (1) HN2012001011A (enExample)
HR (1) HRP20130967T1 (enExample)
IL (1) IL219370A (enExample)
JO (1) JO2887B1 (enExample)
MA (1) MA33751B1 (enExample)
ME (1) ME01537B (enExample)
MX (1) MX2012005691A (enExample)
MY (1) MY160665A (enExample)
NZ (1) NZ600006A (enExample)
PE (1) PE20121430A1 (enExample)
PH (1) PH12012500969A1 (enExample)
PL (1) PL2501703T3 (enExample)
PT (1) PT2501703E (enExample)
RS (1) RS53018B (enExample)
SI (1) SI2501703T1 (enExample)
TW (1) TWI465453B (enExample)
UA (1) UA107943C2 (enExample)
WO (1) WO2011060035A1 (enExample)
ZA (1) ZA201202967B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
DK2903440T3 (en) 2012-10-02 2017-12-11 Bayer Cropscience Ag THETEROCYCLIC COMPOUNDS AS PESTICIDES
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス.エイ. ノシセプチン受容体親和性を有するトリアゾスピロ化合物
CN1516584A (zh) 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
CA2454785C (en) 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
EP1470126A1 (en) * 2002-01-28 2004-10-27 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
CL2009000731A1 (es) 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.

Also Published As

Publication number Publication date
CA2796161A1 (en) 2011-05-19
SI2501703T1 (sl) 2013-11-29
DK2501703T3 (da) 2013-10-14
UA107943C2 (xx) 2015-03-10
PL2501703T3 (pl) 2014-02-28
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
KR20130026523A (ko) 2013-03-13
PT2501703E (pt) 2013-11-26
KR101363830B1 (ko) 2014-02-14
ECSP12011902A (es) 2012-07-31
PH12012500969A1 (en) 2013-01-07
MA33751B1 (fr) 2012-11-01
CN102612520B (zh) 2015-04-08
JO2887B1 (en) 2015-03-15
CO6541545A2 (es) 2012-10-16
CN102612520A (zh) 2012-07-25
WO2011060035A1 (en) 2011-05-19
PE20121430A1 (es) 2012-10-26
US20110118251A1 (en) 2011-05-19
DOP2012000135A (es) 2012-08-15
AU2010319581B2 (en) 2013-12-19
NZ600006A (en) 2014-05-30
IL219370A (en) 2015-01-29
MX2012005691A (es) 2012-06-13
CA2796161C (en) 2015-03-17
HK1169988A1 (en) 2013-02-15
AU2010319581A1 (en) 2012-06-07
EA201290352A1 (ru) 2012-10-30
HN2012001011A (es) 2015-08-31
EA020848B1 (ru) 2015-02-27
TW201127841A (en) 2011-08-16
US8232289B2 (en) 2012-07-31
EP2501703B1 (en) 2013-09-18
ES2435814T3 (es) 2013-12-23
AR078863A1 (es) 2011-12-07
RS53018B (sr) 2014-04-30
ME01537B (me) 2014-04-20
HRP20130967T1 (hr) 2013-11-22
AU2010319581C1 (en) 2014-05-15
EP2501703A1 (en) 2012-09-26
JP5680101B2 (ja) 2015-03-04
IL219370A0 (en) 2012-06-28
JP2013510859A (ja) 2013-03-28
CR20130087A (es) 2013-04-17

Similar Documents

Publication Publication Date Title
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
GB201017345D0 (en) Receptor antagonists
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
IL210857A0 (en) Azaindazole compounds as ccr1 receptor antagonists
SI2547679T1 (sl) Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja
GB2470833A8 (en) Polycyclic antagonists of lysophosphatidic acid receptors.
SI2619212T1 (sl) Analogi buprenorfina kot agonisti in/ali antagonisti opioidnih receptorjev
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
MX350419B (es) Compuesto (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1/antagonistas 5 -ht2a de actividad doble.
PT2590992T (pt) Análogos agonistas do recetor de opioides mu das endomorfinas
MX2010010339A (es) Ciclohexildiaminas sustituidas.
AP2012006630A0 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
PH12013500991A1 (en) 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
MX2013005623A (es) Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
WO2011137331A3 (en) 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
UA50733U (ru) Применение антагониста рецепторов интерлейкина-1 (АРИЛ-1) в качестве средства антиалкогольного действия
UA51902U (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) в качестве способа фригопротекторного действия
UA54879U (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия